BE2014C051I2 - - Google Patents
Download PDFInfo
- Publication number
- BE2014C051I2 BE2014C051I2 BE2014C051C BE2014C051C BE2014C051I2 BE 2014C051 I2 BE2014C051 I2 BE 2014C051I2 BE 2014C051 C BE2014C051 C BE 2014C051C BE 2014C051 C BE2014C051 C BE 2014C051C BE 2014C051 I2 BE2014C051 I2 BE 2014C051I2
- Authority
- BE
- Belgium
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39871102P | 2002-07-25 | 2002-07-25 | |
| PCT/EP2003/050322 WO2004011436A1 (en) | 2002-07-25 | 2003-07-18 | Quinoline derivatives and their use as mycobacterial inhibitors |
| EP03771115A EP1527050B1 (en) | 2002-07-25 | 2003-07-18 | Quinoline derivatives and their use as mycobacterial inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE2014C051I2 true BE2014C051I2 (OSRAM) | 2022-08-09 |
Family
ID=31188461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE2014C051C BE2014C051I2 (OSRAM) | 2002-07-25 | 2014-08-14 |
Country Status (37)
| Country | Link |
|---|---|
| US (1) | US7498343B2 (OSRAM) |
| EP (2) | EP2301544B1 (OSRAM) |
| JP (1) | JP4484703B2 (OSRAM) |
| KR (1) | KR100733577B1 (OSRAM) |
| CN (2) | CN1325475C (OSRAM) |
| AP (1) | AP2421A (OSRAM) |
| AR (1) | AR040673A1 (OSRAM) |
| AT (1) | ATE463482T1 (OSRAM) |
| AU (1) | AU2003262529B2 (OSRAM) |
| BE (1) | BE2014C051I2 (OSRAM) |
| BR (1) | BRPI0312927B8 (OSRAM) |
| CA (1) | CA2493225C (OSRAM) |
| CY (3) | CY1111882T1 (OSRAM) |
| DE (1) | DE60332023D1 (OSRAM) |
| DK (2) | DK2301544T3 (OSRAM) |
| EA (1) | EA008937B1 (OSRAM) |
| ES (2) | ES2395237T3 (OSRAM) |
| FR (1) | FR14C0060I2 (OSRAM) |
| HR (2) | HRP20120190B1 (OSRAM) |
| HU (1) | HUS1400047I1 (OSRAM) |
| IL (2) | IL166457A (OSRAM) |
| IS (1) | IS2914B (OSRAM) |
| LU (1) | LU92520I2 (OSRAM) |
| ME (1) | ME00131B (OSRAM) |
| MX (1) | MXPA05001052A (OSRAM) |
| MY (1) | MY143564A (OSRAM) |
| NL (1) | NL300684I2 (OSRAM) |
| NO (2) | NO329935B1 (OSRAM) |
| NZ (1) | NZ538391A (OSRAM) |
| PL (1) | PL222801B1 (OSRAM) |
| PT (2) | PT1527050E (OSRAM) |
| RS (1) | RS52431B (OSRAM) |
| SI (2) | SI1527050T1 (OSRAM) |
| TW (1) | TWI323730B (OSRAM) |
| UA (1) | UA82198C2 (OSRAM) |
| WO (1) | WO2004011436A1 (OSRAM) |
| ZA (1) | ZA200500680B (OSRAM) |
Families Citing this family (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005070924A1 (en) * | 2004-01-23 | 2005-08-04 | Janssen Pharmaceutica N.V. | Substituted quinolines and their use as mycobacterial inhibitors |
| WO2005070430A1 (en) * | 2004-01-23 | 2005-08-04 | Janssen Pharmaceutica N.V. | Quinoline derivatives and use thereof as mycobacterial inhibitors |
| ES2306098T3 (es) * | 2004-01-29 | 2008-11-01 | Janssen Pharmaceutica Nv | Derivados de quinolina para uso como inhibidores de micobacterias. |
| EP1753427B1 (en) * | 2004-05-28 | 2008-04-02 | Janssen Pharmaceutica N.V. | Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases |
| ME02935B (me) * | 2004-09-28 | 2018-04-20 | Janssen Pharmaceutica Nv | Vezujući domen bakterijske atp sintaze |
| JP2006182755A (ja) * | 2004-12-24 | 2006-07-13 | Janssen Pharmaceut Nv | 潜伏性結核の処置 |
| EE05394B1 (et) * | 2004-12-24 | 2011-04-15 | Janssen Pharmaceutica N.V. | Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis |
| PT1888604E (pt) * | 2005-05-25 | 2012-05-28 | Janssen Pharmaceutica Nv | Processo para preparar (alfa s, beta r)-6-bromo-alfa-[2- (dimetilamino)etil]-2-metoxi-alfa-1-naftalenil-beta-fenil- 3-quinolinoetanol |
| EE05697B1 (et) * | 2005-06-08 | 2014-02-17 | Janssen Pharmaceutica N.V. | Kinoliini derivaadid kui antibakteriaalsed toimeained |
| TWI380819B (zh) * | 2005-06-08 | 2013-01-01 | Janssen Pharmaceutica Nv | 用作抗細菌劑之喹啉衍生物 |
| EA010601B1 (ru) * | 2005-06-09 | 2008-10-30 | Янссен Фармацевтика Н.В. | Производные хинолина в качестве антибактериальных агентов |
| JP5349730B2 (ja) * | 2005-06-09 | 2013-11-20 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 抗バクテリア剤としてのキノリン誘導体 |
| KR101318181B1 (ko) * | 2005-06-09 | 2013-10-16 | 얀센 파마슈티카 엔.브이. | 항균제로서의 퀴놀린 유도체 |
| JO3270B1 (ar) * | 2005-06-28 | 2018-09-16 | Janssen Pharmaceutica Nv | مشتقات كوينولين بصفة عوامل مضادة للبكتيريا |
| JO2752B1 (en) * | 2005-06-28 | 2014-03-15 | شركة جانسين فارماسوتيكا ان. في | Quinoline derivatives acting as antibacterial agents |
| DK1898909T3 (en) * | 2005-06-28 | 2017-02-06 | Janssen Pharmaceutica Nv | QUINOLIN DERIVATIVES AS ANTIBACTERIAL AGENTS |
| JO3077B1 (ar) | 2005-07-28 | 2017-03-15 | Janssen Pharmaceutica Nv | مشتقات كوينولين مضادة للبكتيريا |
| JO2837B1 (en) * | 2005-08-03 | 2014-09-15 | جانسن فارمسيتكا ان في | Quinoline derivatives acting as antibacterial agents |
| JO2855B1 (en) * | 2005-08-03 | 2015-03-15 | شركة جانسين فارماسوتيكا ان. في | Quinoline derivatives acting as antibacterial agents |
| JO2952B1 (en) | 2005-08-03 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Quinoline derivatives acting as antibacterial agents |
| US8686002B2 (en) | 2005-08-21 | 2014-04-01 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as binding partners for 5-HT5 receptors |
| DE102005044817A1 (de) | 2005-09-20 | 2007-03-22 | Sanofi-Aventis Deutschland Gmbh | Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament |
| UA97813C2 (uk) * | 2006-12-05 | 2012-03-26 | Янссен Фармацевтика Н.В. | Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу |
| JO2685B1 (en) * | 2006-12-06 | 2013-03-03 | جانسين فارماسوتيكا ان في | Quinoline antibacterial derivatives |
| JO2970B1 (en) * | 2006-12-06 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Quinoline antibacterial derivatives |
| JO2683B1 (en) * | 2006-12-06 | 2013-03-03 | جانسين فارماسوتيكا ان. في | Quinoline antibacterial derivatives |
| JO2725B1 (en) * | 2006-12-06 | 2013-09-15 | جانسين فارماسوتيكا ان. في | Quinoline antibacterial derivatives |
| JO3271B1 (ar) * | 2006-12-06 | 2018-09-16 | Janssen Pharmaceutica Nv | مشتقات الكوينولين المضادة للجراثيم |
| JO2684B1 (en) * | 2006-12-06 | 2013-03-03 | جانسين فارماسوتيكا ان في | Quinoline antibacterial derivatives |
| RU2404971C2 (ru) * | 2008-12-02 | 2010-11-27 | ЗАО "Фарм-Синтез" | Новые производные хинолина, способ их получения, их применение для лечения микобактериальных инфекций, фармацевтическая композиция на их основе |
| CN102249935B (zh) | 2010-05-17 | 2015-05-20 | 中国人民解放军军事医学科学院毒物药物研究所 | 芳香2-丁醇类化合物及其医药用途 |
| RU2486175C2 (ru) * | 2011-09-12 | 2013-06-27 | Закрытое Акционерное Общество "Фарм-Синтез" | Производные хинолина, в частности 5,6,7-замещенные 1-(2-хлорхинолин-3-ил)-4-диметиламино-2-(нафталин-1-ил)-1-фенилбутан-2-олы, способ получения и применение соединений |
| CN104254527B (zh) | 2012-04-27 | 2017-05-31 | 詹森药业有限公司 | 抗菌的喹啉衍生物 |
| AU2013254670B2 (en) | 2012-04-27 | 2017-03-30 | Janssen Pharmaceutica Nv | Antibacterial quinoline derivatives |
| WO2014014845A1 (en) | 2012-07-18 | 2014-01-23 | Vertex Pharmaceuticals Incorporated | Combination therapy comprising|1 -ethyl-3-[5-[2-{1 -hydroxy-1 -methyl-ethyl}pyrimidin-5-yl]-7-(tetra hydrofuran-2-|yl}-1 h-benzimidazol-2-yl]urea and derivatives thereof to treat mycobacterium|diseases |
| JP6441229B2 (ja) | 2012-12-21 | 2018-12-19 | ヤンセン・サイエンシズ・アイルランド・ユーシー | 抗菌化合物 |
| RU2530493C1 (ru) * | 2013-04-22 | 2014-10-10 | Закрытое Акционерное Общество "Фарм-Синтез" | Производные хинолина, в частности 6,7-замещенные 1-(2-хлорхинолин-3-ил)-4-диметиламино-2-(нафталин-1-ил)-1-фенилбутан-2-олы, способ их получения и применение соединений для лечения инфекционных заболеваний микобактериальной природы, в частности туберкулеза |
| CN105017147B (zh) * | 2014-04-30 | 2019-02-01 | 中国医学科学院药物研究所 | 一种回收和利用Bedaquiline立体化学异构体的方法 |
| CN105085396B (zh) * | 2014-05-07 | 2017-08-08 | 国药集团国瑞药业有限公司 | 用于制备贝达喹啉的中间体及其制备方法和应用 |
| CN105085395B (zh) * | 2014-05-07 | 2017-09-26 | 国药集团国瑞药业有限公司 | 贝达喹啉的制备方法 |
| CN105198808B (zh) * | 2014-05-27 | 2017-08-25 | 北京万生药业有限责任公司 | 一种高效生产贝达喹啉的方法 |
| CN105175329B (zh) * | 2014-06-10 | 2017-09-19 | 重庆圣华曦药业股份有限公司 | 一种贝达喹啉消旋体的合成路线及方法 |
| WO2016008381A1 (zh) * | 2014-07-14 | 2016-01-21 | 辰欣药业股份有限公司 | 吡啶衍生物及其作为抗分支杆菌的应用 |
| CN105330595B (zh) * | 2014-07-14 | 2019-12-10 | 上海嘉坦医药科技有限公司 | 吡啶衍生物及其作为抗分支杆菌的应用 |
| CN105440051B (zh) * | 2014-09-19 | 2019-07-05 | 重庆医药工业研究院有限责任公司 | 一种抗结核的噻吩吡啶衍生物 |
| CZ2014708A3 (cs) | 2014-10-16 | 2016-04-27 | Zentiva, K.S. | Soli Bedaquilinu |
| CZ201533A3 (cs) | 2015-01-21 | 2016-08-03 | Zentiva, K.S. | Způsob izolace směsi enantiomerů |
| CZ201535A3 (cs) | 2015-01-21 | 2016-08-03 | Zentiva, K.S. | Nové možnosti chirální resoluce bedaquilinu |
| CZ201534A3 (cs) | 2015-01-21 | 2016-08-03 | Zentiva, K.S. | Nové možnosti chirální resoluce bedaquilinu |
| FI3250182T3 (fi) | 2015-01-27 | 2023-06-28 | Janssen Pharmaceutica Nv | Dispergoituvia koostumuksia |
| CN108347945B (zh) * | 2015-04-29 | 2021-03-23 | 以色列农业和农村发展部农业研究组织(范卡尼中心) | 抗植物致病组合物 |
| CN106279017A (zh) * | 2015-05-21 | 2017-01-04 | 重庆圣华曦药业股份有限公司 | 贝达喹啉晶型、组合物及其制备方法 |
| CZ2015391A3 (cs) | 2015-06-09 | 2016-12-21 | Zentiva, K.S. | Sůl bedaquilinu s kyselinou citronovou |
| WO2017001660A1 (en) | 2015-07-02 | 2017-01-05 | Janssen Sciences Ireland Uc | Antibacterial compounds |
| CN105061387A (zh) * | 2015-07-17 | 2015-11-18 | 苏州大学 | 二芳基醚类稠环类化合物、制备方法和用途 |
| WO2017015793A1 (zh) * | 2015-07-24 | 2017-02-02 | 浙江海正药业股份有限公司 | 一种分离贝达喹啉非对映异构体a的方法 |
| RU2018111482A (ru) * | 2015-10-20 | 2019-11-21 | Чжэцзян Хисунь Фармасьютикал Ко., Лтд. | Кристаллические формы бедаквилин фумарата и способы их получения |
| WO2017121323A1 (zh) * | 2016-01-13 | 2017-07-20 | 辰欣药业股份有限公司 | 一种吡啶衍生物类化合物的制备方法及其中间体和晶型 |
| CN108699047B (zh) * | 2016-03-03 | 2022-03-11 | 科学与工业研究委员会 | 作为抗分枝杆菌药剂的取代的橙酮生物碱 |
| CA3016068C (en) * | 2016-03-07 | 2024-02-27 | The Global Alliance For Tb Drug Development, Inc. | Antibacterial compounds and uses thereof |
| JP2019518050A (ja) | 2016-06-16 | 2019-06-27 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | 抗菌薬としての複素環式化合物 |
| JP2019518046A (ja) | 2016-06-16 | 2019-06-27 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | 抗菌薬としての複素環式化合物 |
| WO2018158280A1 (en) | 2017-03-01 | 2018-09-07 | Janssen Sciences Ireland Uc | Combination therapy |
| SI3943070T1 (sl) | 2017-07-14 | 2024-03-29 | Janssen Pharmaceutica Nv, | Dolgo delujoče formulacije bedakilina |
| CN109384716B (zh) * | 2017-08-11 | 2021-06-29 | 海创药业股份有限公司 | 一种氘代喹啉化合物及其制备和用途 |
| WO2020144197A1 (en) | 2019-01-09 | 2020-07-16 | Janssen Pharmaceutica Nv | Combination in the treatment of nontuberculous mycobacterial diseases |
| US12479816B2 (en) | 2019-02-08 | 2025-11-25 | University of Pittsburgh—of the Commonwealth System of Higher Education | 20-HETE formation inhibitors |
| WO2020161743A1 (en) | 2019-02-08 | 2020-08-13 | Mylan Laboratories Limited | Process for the preparation of bedaquiline fumarate |
| WO2021048342A1 (en) | 2019-09-13 | 2021-03-18 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| CN112574175B (zh) * | 2019-09-29 | 2023-11-14 | 南京长澳医药科技有限公司 | 喹啉类化合物、其制备方法和用途 |
| CA3151712A1 (en) | 2019-09-30 | 2021-04-08 | Jerome Emile Georges Guillemont | Cytochrome bd inhibitors as anti-bacterial agents for the treatment of tuberculosis |
| MX2022003814A (es) | 2019-09-30 | 2022-05-06 | Janssen Sciences Ireland Unlimited Co | Compuestos antibacterianos de 4-quinolinona. |
| CN110804016B (zh) * | 2019-12-05 | 2022-11-04 | 福建省微生物研究所 | 抗结核分枝杆菌的二芳基喹啉衍生物 |
| IL294363B2 (en) | 2019-12-27 | 2025-09-01 | Tecnimede Soc T?Cnico Medicinal Sa | Antibacterial quinolines |
| KR102303635B1 (ko) | 2020-07-01 | 2021-09-17 | 동아에스티 주식회사 | (1r,2s)-1-(6-브로모-2-메톡시퀴놀린-3-일)-4-디메틸아미노-2-(1-나프틸)-1-페닐-부탄-2-올 및 이의 약제학적으로 허용 가능한 염의 제조방법 |
| MX2023000439A (es) | 2020-07-09 | 2023-02-09 | Janssen Pharmaceutica Nv | Formulaciones a largo plazo. |
| CA3182854A1 (en) | 2020-07-09 | 2022-01-13 | Rene Holm | Long-acting formulations |
| US20240277614A1 (en) | 2020-07-09 | 2024-08-22 | Janssen Pharmaceutica Nv | Long-acting formulations |
| KR20230107275A (ko) | 2020-11-12 | 2023-07-14 | 얀센 파마슈티카 엔.브이. | 비결핵성 마이코박테리아 질환의 치료에서 베다퀼린, 에탐부톨 및 마크롤라이드의 조합물 |
| KR20230157400A (ko) | 2021-03-16 | 2023-11-16 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 항박테리아성 화합물 |
| CA3211592A1 (en) | 2021-03-17 | 2022-09-22 | Jerome Emile Georges Guillemont | Antibacterial compounds |
| CN117440958A (zh) | 2021-03-17 | 2024-01-23 | 爱尔兰詹森科学公司 | 抗菌化合物 |
| WO2022214519A1 (en) | 2021-04-07 | 2022-10-13 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| WO2022214520A1 (en) | 2021-04-07 | 2022-10-13 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| CA3223626A1 (en) | 2021-06-29 | 2023-01-05 | Augusto Eugenio Pardal Filipe | Heterocyclic compounds for the treatment of tuberculosis |
| CN118159543A (zh) | 2021-10-28 | 2024-06-07 | 爱尔兰詹森科学公司 | 在治疗细菌感染中使用的咪唑并吡啶酰胺和相关化合物 |
| WO2023150747A1 (en) | 2022-02-07 | 2023-08-10 | Insmed Incorporated | Dry powder compositions of bedaquiline and salts and methods of use thereof |
| CN114835641B (zh) * | 2022-05-07 | 2024-03-15 | 南京杰运医药科技有限公司 | 一种3-苄基-6-溴-2-甲氧基喹啉的合成方法 |
| WO2023217279A1 (zh) * | 2022-05-13 | 2023-11-16 | 广州嘉越医药科技有限公司 | 一种吡啶衍生物、中间体、制备方法和应用 |
| WO2023232838A1 (en) | 2022-05-31 | 2023-12-07 | Janssen Pharmaceutica Nv | Bedaquiline for use in the treatment of leprosy |
| WO2024068693A1 (en) | 2022-09-28 | 2024-04-04 | Janssen Pharmaceutica Nv | Long-acting formulations |
| WO2024068699A1 (en) | 2022-09-28 | 2024-04-04 | Janssen Pharmaceutica Nv | Long-acting formulations |
| WO2024089170A1 (en) | 2022-10-27 | 2024-05-02 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| CN120225518A (zh) * | 2022-11-15 | 2025-06-27 | 伊莱利利公司 | Ahr激动剂 |
| WO2024223859A1 (en) | 2023-04-26 | 2024-10-31 | Janssen Pharmaceutica Nv | Antibacterial compounds |
| WO2025068448A1 (en) | 2023-09-28 | 2025-04-03 | Janssen Pharmaceutica Nv | Atp synthase inhibitors for use in the treatment of non-tuberculosis mycobacteria |
| WO2025181475A1 (en) | 2024-02-27 | 2025-09-04 | The University Of Liverpool | Novel tuberculosis sterilization formulations |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998018326A1 (en) * | 1996-10-28 | 1998-05-07 | Department Of The Army, U.S. Government | Compounds, compositions and methods for treating antibiotic-resistant infections |
| US6103905A (en) * | 1997-06-19 | 2000-08-15 | Sepracor, Inc. | Quinoline-indole antimicrobial agents, uses and compositions related thereto |
| US6172084B1 (en) * | 1997-06-19 | 2001-01-09 | Sepracor, Inc. | Quinoline-indole antimicrobial agents, uses and compositions related thereto |
| AU6645198A (en) * | 1998-01-23 | 1999-08-09 | Fire Armour Pte Ltd | Nozzle with axially and perpendicularly directed apertures |
| ES2201674T3 (es) * | 1998-01-26 | 2004-03-16 | Smithkline Beecham Plc | Derivados de quinolina con propiedades antibacterianas. |
| US6819431B2 (en) * | 2001-07-06 | 2004-11-16 | Zygo Corporation | Polymer retarder |
| EE05394B1 (et) * | 2004-12-24 | 2011-04-15 | Janssen Pharmaceutica N.V. | Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis |
| EE05697B1 (et) * | 2005-06-08 | 2014-02-17 | Janssen Pharmaceutica N.V. | Kinoliini derivaadid kui antibakteriaalsed toimeained |
-
2003
- 2003-07-18 DK DK10154018.5T patent/DK2301544T3/da active
- 2003-07-18 HR HRP20120190AA patent/HRP20120190B1/hr not_active IP Right Cessation
- 2003-07-18 EA EA200500257A patent/EA008937B1/ru active Protection Beyond IP Right Term
- 2003-07-18 DK DK03771115.7T patent/DK1527050T3/da active
- 2003-07-18 AP AP2005003210A patent/AP2421A/xx active
- 2003-07-18 NZ NZ538391A patent/NZ538391A/en not_active IP Right Cessation
- 2003-07-18 UA UAA200501778A patent/UA82198C2/uk unknown
- 2003-07-18 CN CNB038177137A patent/CN1325475C/zh not_active Expired - Lifetime
- 2003-07-18 SI SI200331819T patent/SI1527050T1/sl unknown
- 2003-07-18 MX MXPA05001052A patent/MXPA05001052A/es active IP Right Grant
- 2003-07-18 BR BRPI0312927A patent/BRPI0312927B8/pt not_active IP Right Cessation
- 2003-07-18 PL PL375523A patent/PL222801B1/pl unknown
- 2003-07-18 WO PCT/EP2003/050322 patent/WO2004011436A1/en not_active Ceased
- 2003-07-18 PT PT03771115T patent/PT1527050E/pt unknown
- 2003-07-18 CA CA2493225A patent/CA2493225C/en not_active Expired - Lifetime
- 2003-07-18 ES ES10154018T patent/ES2395237T3/es not_active Expired - Lifetime
- 2003-07-18 KR KR1020057000447A patent/KR100733577B1/ko not_active Expired - Lifetime
- 2003-07-18 AT AT03771115T patent/ATE463482T1/de active
- 2003-07-18 EP EP10154018A patent/EP2301544B1/en not_active Expired - Lifetime
- 2003-07-18 ES ES03771115T patent/ES2343458T3/es not_active Expired - Lifetime
- 2003-07-18 CN CN2007101049477A patent/CN101070304B/zh not_active Expired - Lifetime
- 2003-07-18 HR HRP20050045AA patent/HRP20050045B1/hr not_active IP Right Cessation
- 2003-07-18 JP JP2004523812A patent/JP4484703B2/ja not_active Expired - Lifetime
- 2003-07-18 RS YU20050058A patent/RS52431B/sr unknown
- 2003-07-18 ME MEP-2008-92A patent/ME00131B/me unknown
- 2003-07-18 AU AU2003262529A patent/AU2003262529B2/en not_active Expired
- 2003-07-18 EP EP03771115A patent/EP1527050B1/en not_active Expired - Lifetime
- 2003-07-18 SI SI200332211T patent/SI2301544T1/sl unknown
- 2003-07-18 PT PT101540185T patent/PT2301544E/pt unknown
- 2003-07-18 DE DE60332023T patent/DE60332023D1/de not_active Expired - Lifetime
- 2003-07-24 TW TW092120160A patent/TWI323730B/zh active
- 2003-07-24 AR AR20030102655A patent/AR040673A1/es active IP Right Grant
- 2003-07-24 MY MYPI20032793A patent/MY143564A/en unknown
-
2004
- 2004-12-08 US US11/007,026 patent/US7498343B2/en active Active
- 2004-12-29 IS IS7620A patent/IS2914B/is unknown
-
2005
- 2005-01-24 ZA ZA200500680A patent/ZA200500680B/xx unknown
- 2005-01-24 IL IL166457A patent/IL166457A/en active IP Right Grant
- 2005-01-27 NO NO20050476A patent/NO329935B1/no not_active IP Right Cessation
-
2009
- 2009-12-10 IL IL202655A patent/IL202655A/en active IP Right Grant
-
2010
- 2010-07-07 CY CY20101100634T patent/CY1111882T1/el unknown
-
2012
- 2012-12-19 CY CY20121101241T patent/CY1113497T1/el unknown
-
2014
- 2014-08-14 CY CY2014033C patent/CY2014033I2/el unknown
- 2014-08-14 BE BE2014C051C patent/BE2014C051I2/nl unknown
- 2014-08-14 NL NL300684C patent/NL300684I2/nl unknown
- 2014-08-14 HU HUS1400047C patent/HUS1400047I1/hu unknown
- 2014-08-14 LU LU92520C patent/LU92520I2/xx unknown
- 2014-08-18 FR FR14C0060C patent/FR14C0060I2/fr active Active
- 2014-08-20 NO NO2014021C patent/NO2014021I1/no not_active IP Right Cessation